Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Anderlecht – page 19

441 clinical trials in Anderlecht, Belgium across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Anderlecht at a glance
441
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

441 trials in Anderlecht

Open in trial search

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on the Effects of Semaglutide in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis Stages 2 or 3

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on the Effectiveness of NNC0194-0499 and Semaglutide in Treating Non-Alcoholic Steatohepatitis (NASH) in Patients with Fibrosis Stages 2-4

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Hypereosinophilic syndrome

Not recruiting

Study of benralizumab compared to placebo for treatment of patients with Hypereosinophilic Syndrome (HES)

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Systemic scleroderma

Not recruiting

Study of anifrolumab effectiveness compared to placebo in adults aged 18-70 with systemic sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Systemic scleroderma

Not recruiting

Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Axial spondyloarthritis

Not recruiting

Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Hypertriglyceridaemia

Not recruiting

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Chronic kidney disease

Not recruiting

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Type 2 diabetes mellitus

Not recruiting

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Anderlecht

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials investigating new treatments for various cancers, including bladder cancer, acute myeloid leukemia, and advanced breast cancer. Studies focus on innovative combination therapies and targeted treatments.

  • Non-muscle invasive bladder cancer therapy
  • Metastatic breast cancer treatments
  • Gastroesophageal cancer interventions
02 Immunology and Inflammatory Conditions

Clinical investigations targeting chronic inflammatory conditions and autoimmune disorders, including Crohn's Disease, Ulcerative Colitis, and Psoriatic Arthritis.

  • Inflammatory bowel disease therapies
  • Novel arthritis treatments
  • Sjögren's Disease interventions
03 Infectious Diseases

Studies examining innovative approaches to combat various infections, including urinary tract infections and viral diseases. Research includes vaccine development and antimicrobial therapies.

  • UTI vaccine development
  • RSV vaccination studies
  • Hepatitis D treatments
04 Cardiovascular and Pulmonary Studies

Research focusing on pulmonary hypertension and cardiovascular disease management, with emphasis on innovative therapeutic approaches and disease prevention.

  • Pulmonary arterial hypertension treatments
  • Cardiovascular disease interventions
  • Post-cardiac arrest care
Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.